加载中
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
收盘时
US$1.16
−US$0.02 · -1.69%
盘后
US$1.17
+US$0.01 · +0.86%
10月13日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
日内区间
当前US$1.16
52周区间
当前US$1.16
盘中时间采用ET。市场数据可能有所延迟。
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
日内区间
当前US$1.16
52周区间
当前US$1.16
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 145.47亿 USD | 1000.92万 USD | 1111.23万 USD | 893.33万 USD | 345.31万 USD |
| 销售、一般及管理费用 | 97.22亿 USD | 694.8万 USD | 907.01万 USD | 614.35万 USD | 428.98万 USD |
| 营业费用 | 2426.97万 USD | 1695.72万 USD | 2018.24万 USD | 1617.62万 USD | 778.66万 USD |
| 利息收入 | 31.4万 USD | 31.84万 USD | 2.76万 USD | 1870 USD | 2012 USD |
| 利息支出 | — | 57 USD | — | 6967 USD | 82.75万 USD |
| 营业利润 | −2426.97万 USD | −1695.72万 USD | −2018.24万 USD | −1617.62万 USD | −778.66万 USD |
| 净利润 | −2239.62万 USD | −2325.47万 USD | −1977.29万 USD | −1576.93万 USD | −1250.39万 USD |
公司数据更新于 2026年10月14日。
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
